ReviewBioMed research international2014
Application of proteomics and peptidomics to COPD.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Clinical peptidomics for respiratory diseases: matrices, workflows, and translation towards treatable traits, with a focus on COPD.Clinical proteomics · 2026Review
- Molecular profiling of exhaled breath condensate in respiratory diseases.Annals of medicine · 2025Review
- Review
- An integrated metabo-lipidomics profile of induced sputum for the identification of novel biomarkers in the differential diagnosis of asthma and COPD.Journal of translational medicine · 2024Article
- Prognostic Biomarkers Based on Proteomic Technology in COPD: A Recent Review.International journal of chronic obstructive pulmonary disease · 2023Review
- Proteomic Analysis of Human Sputum for the Diagnosis of Lung Disorders: Where Are We Today?International journal of molecular sciences · 2022Review
- Application of Proteomics in Sarcoidosis.American journal of respiratory cell and molecular biology · 2020Review
- Free Urinary Desmosine and Isodesmosine as COPD Biomarkers: The Relevance of Confounding Factors.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2016Article
- [COPD: An early disease].Revue de pneumologie clinique · 2016Review
- Diagnostic yield and safety of C-TBNA in elderly patients with lung cancer.Open medicine (Warsaw, Poland) · 2016Article
- Cushing's like syndrome in typical bronchial carcinoid a case report and review of the literature.International journal of surgery case reports · 2016Article
- Role of FDG-PET scan in staging of pulmonary epithelioid hemangioendothelioma.Open medicine (Warsaw, Poland) · 2016Article
- Prenatal diagnosis, 3-D virtual rendering and lung sparing surgery by ligasure device in a baby with "CCAM and intralobar pulmonary sequestration".Open medicine (Warsaw, Poland) · 2016Article
- Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia.Open medicine (Warsaw, Poland) · 2016Article
- Hemangiomas of the maxillofacial area: Case Report, Classification and Treatment Planning.Open medicine (Warsaw, Poland) · 2015Article
- Sirtuin 1 and aging theory for chronic obstructive pulmonary disease.Analytical cellular pathology (Amsterdam) · 2015Review
- Integrative genomics of chronic obstructive pulmonary disease.Biochemical and biophysical research communications · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a complex disorder involving both airways and lung parenchyma, usually associated with progressive and poorly reversible airflow limitation. In order to better characterize the phenotypic heterogeneity and the prognosis of patients with COPD, there is currently an urgent need for discovery and validation of reliable disease biomarkers. Within this context, proteomic and peptidomic techniques are emerging as very valuable tools that can be applied to both systemic and pulmonary samples, including peripheral blood, induced sputum, exhaled breath condensate, bronchoalveolar lavage fluid, and lung tissues. Identification of COPD biomarkers by means of proteomic and peptidomic approaches can thus also lead to discovery of new molecular targets potentially useful to improve and personalize the therapeutic management of this widespread respiratory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.